[
  {
    "ts": null,
    "headline": "Bastion Bets on Government Spending with $8 Million New Stake in Parsons",
    "summary": "Parsons delivers technology-driven solutions for defense, intelligence, and critical infrastructure clients across North America and beyond.",
    "url": "https://finnhub.io/api/news?id=0686251e8826c85513c5a20960ed26d8a0e51f73122ff1ca465bc49619cb52e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772225843,
      "headline": "Bastion Bets on Government Spending with $8 Million New Stake in Parsons",
      "id": 139257216,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Parsons delivers technology-driven solutions for defense, intelligence, and critical infrastructure clients across North America and beyond.",
      "url": "https://finnhub.io/api/news?id=0686251e8826c85513c5a20960ed26d8a0e51f73122ff1ca465bc49619cb52e4"
    }
  },
  {
    "ts": null,
    "headline": "IHE: U.S. Pharmaceuticals ETF With Excellent GARP Features",
    "summary": "IHE: U.S. Pharmaceuticals ETF With Excellent GARP Features",
    "url": "https://finnhub.io/api/news?id=fd445e2724625e6a109ff734f0648892f87df7df2e8e983c77c57a0bb579559e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772209080,
      "headline": "IHE: U.S. Pharmaceuticals ETF With Excellent GARP Features",
      "id": 139256613,
      "image": "",
      "related": "VTRS",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=fd445e2724625e6a109ff734f0648892f87df7df2e8e983c77c57a0bb579559e"
    }
  },
  {
    "ts": null,
    "headline": "Viatris Inc. (VTRS) FDA Accepts sNDA for Presbyopia Treatment with October PDUFA Date",
    "summary": "Viatris Inc. (NASDAQ:VTRS) is one of the most undervalued stocks under $30 to buy. On February 25, Viatris announced that the FDA accepted its sNDA for MR-141, which is a phentolamine ophthalmic solution 0.75% intended to treat presbyopia. The FDA set a PDUFA goal date of October 17 this year, to complete its review. Presbyopia […]",
    "url": "https://finnhub.io/api/news?id=23194275f9a5d16084688433724911efffc94a09fcebfc5310810a2664372e28",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772193765,
      "headline": "Viatris Inc. (VTRS) FDA Accepts sNDA for Presbyopia Treatment with October PDUFA Date",
      "id": 139247515,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Viatris Inc. (NASDAQ:VTRS) is one of the most undervalued stocks under $30 to buy. On February 25, Viatris announced that the FDA accepted its sNDA for MR-141, which is a phentolamine ophthalmic solution 0.75% intended to treat presbyopia. The FDA set a PDUFA goal date of October 17 this year, to complete its review. Presbyopia […]",
      "url": "https://finnhub.io/api/news?id=23194275f9a5d16084688433724911efffc94a09fcebfc5310810a2664372e28"
    }
  },
  {
    "ts": null,
    "headline": "A Look At Viatris (VTRS) Valuation After Earnings Beat And 2026 Guidance Update",
    "summary": "Viatris (VTRS) shares reacted to a busy update cycle after the company reported a fourth quarter revenue and adjusted earnings beat, along with fresh 2026 guidance, a cost saving plan, and refreshed capital return commitments. See our latest analysis for Viatris. Even after a 5.16% one day share price decline and a 4.57% seven day share price pullback around the earnings release and guidance, Viatris is still up 16.23% on a 30 day share price basis and 42.66% over 90 days. Its 1 year total...",
    "url": "https://finnhub.io/api/news?id=be03e40368584e03dca50c27657f19c9d6563068db5802cb46701874ad999349",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772183659,
      "headline": "A Look At Viatris (VTRS) Valuation After Earnings Beat And 2026 Guidance Update",
      "id": 139245529,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Viatris (VTRS) shares reacted to a busy update cycle after the company reported a fourth quarter revenue and adjusted earnings beat, along with fresh 2026 guidance, a cost saving plan, and refreshed capital return commitments. See our latest analysis for Viatris. Even after a 5.16% one day share price decline and a 4.57% seven day share price pullback around the earnings release and guidance, Viatris is still up 16.23% on a 30 day share price basis and 42.66% over 90 days. Its 1 year total...",
      "url": "https://finnhub.io/api/news?id=be03e40368584e03dca50c27657f19c9d6563068db5802cb46701874ad999349"
    }
  }
]